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Summary
The Rho family of GTPases regulates many aspects of
cellular behavior through alterations to the actin cyto-
skeleton [1–6]. The majority of the Rho family proteins
function as molecular switches cycling between the
active, GTP-bound and the inactive, GDP-bound con-
formations [1–6]. Unlike typical Rho-family proteins,
the Rnd subfamily members, including Rnd1, Rnd2,
RhoE (also known as Rnd3), and RhoH, are GTPase
deficient and are thus expected to be constitutively
active [7–10]. Here, we identify an unexpected role
for RhoE/Rnd3 in the regulation of the p53-mediated
stress response. We show that RhoE is a transcrip-
tional p53 target gene and that genotoxic stress trig-
gers actin depolymerization, resulting in actin-stress-
fiber disassembly through p53-dependent RhoE
induction. Silencing of RhoE induction in response
to genotoxic stress maintains stress fiber formation
and strikingly increases apoptosis, implying an antag-
onistic role for RhoE in p53-dependent apoptosis. We
found that RhoE inhibits ROCK I (Rho-associated ki-
nase I) activity during genotoxic stress and thereby
suppresses apoptosis. We demonstrate that the p53-
mediated induction of RhoE in response to DNA dam-
age favors cell survival partly through inhibition of
ROCK I-mediated apoptosis. Thus, RhoE is antici-
pated to function by regulating ROCK I signaling to
control the balance between cell survival and cell
death in response to genotoxic stress.
*Correspondence: sam.lee@cbrc2.mgh.harvard.eduResults and Discussion
We identified RhoE (also known as Rnd3) as a p53-
responsive gene through a DNA-chip expression array
that compared gene expression in the presence or ab-
sence of p53. To confirm this data, we looked for upre-
gulation of RhoE mRNA and protein in the p53-inducible
EJ cell line and through adenoviral (Ad) expression of
p53 in p53-null Saos2 cells (Figure 1; also Figure S1 in
the Supplemental Data available online). Because p53
is important in the DNA-damage response, the levels
of RhoE mRNA and protein (Figure 1B; Figure S1) were
studied in several p53-positive and -negative cell lines
after treatment with various DNA-damaging agents: mi-
tomycin C (MMC), etoposide (ETO), and camptothecin
(CPT). RhoE was induced in response to p53 or DNA
damage in cells containing wild-type p53 with kinetics
similar to those of the p53-dependent gene, p21 (Fig-
ure 1A). Inhibition of p53 activation in response to DNA
damage, by means of p53 siRNA, abrogated RhoE
induction (Figure 1B). We next investigated whether
RhoE could be a direct p53 transcription target by map-
ping the transcriptional start site in a 50 RACE experi-
ment and found three potential p53-binding sites (p53-
BS) in the RhoE promoter; these sites matched the
consensus p53 binding sequence by 80%–90% and
contained the required conserved nucleotide sequence
[11] (Figure 1C). To test the p53 response of these sites
on the RhoE promoter, we linked the promoter, contain-
ing the three potential binding sites at positions 2249,
2580, and22220, to a luciferase reporter gene. Cotrans-
fection of the construct with a wt-p53 expression plas-
mid into p53 null Saos2 cells increased luciferase activity
significantly, whereas cotransfection with vector alone
(Figure 1C) or mutant p53 (V143A) failed to do so (data
not shown). We next generated point mutations at
several consensus sequences of the three potential
p53-BS in the RhoE promoter. A luciferase construct
mutated at the 22220 position (designated M-1) signifi-
cantly decreased luciferase activity in response to wt-
p53, whereas mutations in either the2249 or2580 sites
had little effect on luciferase activity (Figure 1C). We
transfected U2OS cells, containing wt-p53, with the lu-
ciferase constructs, then treated them with CPT for 24
hr to test the ability of endogenous p53 to activate the
putative p53-BS in the RhoE promoter. These results
confirm the data obtained in Saos2 cells, where tran-
scriptional activity was only affected upon mutation of
the 22200 p53-BS (Figure 1C). To determine whether
p53 could bind to the RhoE promoter in vivo, we carried
out a chromatin immunoprecipitation (ChIP) assay in
Saos2 cells infected with Ad-p53 or Ad-GFP. The RhoE
genomic fragment containing the 22200 p53-BS was
specifically immunoprecipitated as a p53 protein-DNA
complex with a p53 antibody but not with an HA
antibody (Figure 1D; Figure S1). PCR amplification
of a region containing a p53-binding site in the p21 pro-
moter served as a positive control (Figure 1D). In order to
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2467Figure 1. p53-Dependent Induction of RhoE
(A) RhoE mRNA is induced after tetracycline (tet) removal in EJ-p53 cells (tet-off). Total RNA was prepared from these samples, and northern
blots were performed sequentially with 32P-labeled probe against RhoE, p21, and 36B4 (loading control). Total RNA was prepared from other
p53+/+ and p532/2 cell lines after mitomycin C (MMC, 1 mg/ml) or etoposide (ETO, 25 mM) treatment at the indicated times.
(B) U2OS and Saos2 cells were transfected with siRNA oligos targeting wt-p53 or luciferase control for 1 day, then treated with either 25 mM of
ETO for 24 hr (U20S) or infected with adenovirus expressing p53 (Ad-p53) or Ad-GFP control (Saos2). Protein extracts were immunoblotted with
RhoE, p21, p53, and b-actin antibodies.
(C) The p53-binding site at -2200 is responsible for RhoE transcription. Luciferase assay reporter gene constructs containing the putative p53-
recognition sequences within the RhoE promoter were co-transfected into Saos2 cells with either wt-p53 or control expression constructs. U2OS
cells were also transfected with the reporter plasmids, then treated with 600 nM camptothecin (CPT) for 24 hr. The reporter plasmids used were
the following: empty PGL3 vector, the full-length (FL) promoter, and six reporter constructs with p53-binding-site mutations (M1-M6); the p21
promoter was used as a control. The putative p53-recognition sequence within the RhoE promoter and the p53-consensus binding sequences
(BS) are shown. Error bars represent the standard deviation from three independent experiments.
(D) Chromatin immunoprecipitation (ChIP)assayof p53DNAbinding to theRhoEpromoter.Saos2cellswere infectedwith Ad-p53or Ad-GFPfor24hr,
then ChIP was performed with either a p53 antibody or an HA-tag antibody (negative control). U2OS cells were also used for ChIP analysis of endog-
enous p53 activity upon DNA damage by 24 hr treatment with 600 nM CPT. Amplification products were 235 bp (RhoE) and 417 bp (p21), respectively.examine whether endogenous p53 could bind to the
RhoE promoter in vivo after DNA damage, we per-
formed a ChIP assay in CPT-treated U2OS cells. Thesame genomic fragments were amplified from com-
plexes immunoprecipitated with a p53-specific antibody
but not with control IgG in DNA-damaged U2OS cells
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2468Figure 2. RNAi Ablation of Endogenous RhoE Induction in Response to Genotoxic Stress Restores Stress-Fiber Formation and Enhances
Apoptosis
(A) Expression of RhoE protein and mRNA in RhoE knockdown cells. RhoE expression was analyzed by northern- and western-blot analysis
in U2OS cells transiently transfected with shRNA against RhoE (R1, R2) or control scrambled RhoE shRNA (C1, C2), then treated the following
day with 600 nM CPT for the indicated times.
(B) RhoE effects actin-stress-fiber formation in response to genotoxic stress. U2OS cells stably transfected with RhoE shRNA (R1) or scram-
bled RhoE shRNA plasmids were treated with CPT (600 nM) for 24 hr. Cells were stained for filamentous actin with rhodamine-conjugated
phalloidin.
(C) RhoE depletion increases genotoxic-stress-induced apoptosis. U2OS cells stably transfected with RhoE shRNA or scrambled RhoE shRNA
plasmids were exposed to CPT (600 nM) or ETO (25 mM) for 24 hr. The M1 cell population represents the percentage of sub-G1 cells from each
sample as calculated from three independent experiments. The percentages in the right panel indicate the number of apoptotic cells, which stain
Annexin V positive and PI negative.
(D) DNA-damage-induced cell blebbing is increased by RhoE knockdown. U2OS cells expressing control (scrambled) or RhoE shRNA plasmids
were cultured on cover glass and treated with 600 nM CPT or DMSO for 48 hr, then imaged by phase-contrast microscopy. Arrows indicate cells
with membrane blebbing. The percentage of cells that bleb at 32 hr was quantified and represents the mean 6 S.E.M. of three experiments.(Figure 1D). Although the fragments were present in both
DMSO- and CPT-treated U2OS cells, there was a signifi-
cant increase in the amount of DNA amplified from the
complexes of the DNA-damaged cells. ChIP assays per-
formed with primers specific to either the 2249 or the
2580 p53-BS in the RhoE promoter demonstrated no
significant binding (data not shown). These results indi-
cate that RhoE is a transcriptional target of p53 and that
the 22220 p53-BS plays a role in p53-mediated RhoE
transcription.
To investigate whether RhoE induction in response to
genotoxic stress contributes directly to p53-dependent
stress responses, we used RhoE shRNA in the pBabe-
U6-shRNA retroviral vector to knock down the inductionof endogenous RhoE in response to DNA damage.
Transfection of RhoE shRNA resulted in the suppression
of endogenous RhoE induced by CPT treatment of U2OS
cells, whereas control shRNA (scrambled) had no effect
(Figure 2A). To exclude off-target effects of shRNA, we
used two independent RhoE shRNAs, both of which
reduced RhoE expression (Figure 2A). In subsequent ex-
periments, the data presented incorporated the R1 RhoE
shRNA and the results confirmed by transfection of R2.
RhoE is known to inhibit RhoA-mediated ROCK signal-
ing and block actin-stress-fiber formation [7, 8, 10, 12,
13]. CPT treatment of U2OS cells induced a dramatic loss
of actin stress fibers, as indicated by F-actin staining,
whereas DMSO-treated cells maintained actin stress
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2469Figure 3. Effect of RhoE on ROCK I Kinase
Activity during Genotoxic Stress
(A) Inhibition of RhoE expression enhances
ROCK I kinase activity in wt-p53-expressing
cells. U2OS cells stably expressing scram-
bled RhoE-shRNA and RhoE-shRNA were
treated with CPT for 12 or 24 hr. Cell lysates
were subjected to immunoprecipitation (IP)
with 2 mg of ROCK I antibody and western
blotted so that the levels of ROCK I and
RhoE could be examined. The IP pallets
were assayed for Rho kinase activity with
MYPT1 as the substrate. The assay mixture
was then subjected to SDS-PAGE. The gel
was dried and autoradiographed. The band
corresponding to MYPT1 was excised and
quantified by scintillation counting. (B) Ef-
fects of RhoE overexpression on ROCK I ki-
nase activity in 293ET cells containing dys-
functional p53. 293ET cells were transfected
with control and RhoE expression vector for
24 hr. The cells were then treated with 600
nM CPT for 24 and 32 hr, immunoprecipi-
tated, and analyzed as described in (A).
All error bars represent the standard devia-
tion from three individual experiments.fibers (Figure 2B). Depletion of RhoE by shRNA in CPT-
treated U2OS cells, as compared to cells expressing
control shRNA, caused a reproducible recovery of actin
stress fibers (Figure 2B), suggesting that RhoE induction
was required for the DNA-damage-mediated loss of
actin stress fibers. This recovery of actin stress fibers
upon ablation of RhoE is consistent with overexpression
studies showing that RhoE inhibits actin-stress-fiber
formation [7, 8, 12]. Furthermore, suppression of RhoE in
response to genotoxic insult resulted in a significant in-
crease in apoptosis from approximately 20% to approx-
imately 50% as measured by flow-cytometry analysis
of cells stained with propidium iodide (PI) or by Annexin
V/PI costaining (Figure 2C). To confirm the p53 depen-
dence of RhoE’s effect on apoptosis and to demonstrate
that this result is not limited to U2OS cells, we repeated
these experiments in normal dermal fibroblasts (IMR90),
p53-null Saos2 cells, and p53+/+ and p532/2 HCT116
cells (Figures S2 and S3). p53 wild-type cells transiently
transfected with shRhoE were able to enhance CPT-
induced apoptosis, as measured by TUNEL and DNA
fragmentation assays (Figures S2 and S3). However,
there was no noticeable change in the DNA-damage re-
sponse upon RhoE knockdown in p53-null cells (Figures
S2 and S3). Although increased stress fiber formation
was observed upon inhibition of RhoE and treatmentwith CPT (Figure 2B), at later time points we were able
to see an increase in membrane blebbing, a hallmark of
cellular apoptosis, in these cells compared to control
cells (Figure 2D).
The concomitant increase in actin fibers and cell
death in RhoE-depleted cells treated by DNA damage
suggests a link between RhoE-mediated inhibition of
actin-stress-fiber formation and ROCK I-mediated cell
death. ROCK I is an emerging protein kinase that is re-
sponsible for membrane blebbing in apoptotic cells
[14–19]. Owing to the facts that RhoE interacts with
ROCK I and that RhoE overexpression inhibits ROCK I-
induced myosin light chain (MLC) phosphorylation [12,
19], we investigated whether RhoE induction by DNA
damage inhibits ROCK I kinase activity. We determined
the effect of RhoE depletion on endogenous ROCK I
kinase activity by measuring the level of MYPT1 (regula-
tory subunit of MLC-phosphatase) phosphorylation.
Although CPT-treated U2OS cells increased ROCK I
activation more than 2-fold, depletion of RhoE in
CPT-treated cells further increased ROCK I activity
(Figure 3A). We also examined the effect of RhoE over-
expression on ROCK I activity in CPT-treated 293ET
cells containing dysfunctional p53. CPT treatment in-
creased ROCK I activity in 293ET cells, but RhoE expres-
sion was not induced as a result of the lack of p53.
Current Biology
2470Figure 4. Effect of ROCK I Inhibition on Apoptosis
(A) ROCK I activation/cleavage upon genotoxic stress. U2OS cells stably transfected with control (scrambled), ROCK I, or RhoE shRNA plasmids
were treated with 600 nM CPT for 24 hr. Immunoblotting with antibodies to both the C terminus (top panel) and the N terminus of ROCK I (bottom
panel) allowed the cleavage of ROCK I to be assessed. The cell lysates were further blotted for cleaved PARP, RhoE, p53, and b-actin.
(B and C) shRNA ablation of ROCK I expression inhibits the rate of apoptosis. U2OS (B) and HCT116 p53+/+ cells (C) expressing the shRNA
plasmids were treated with 600 nM CPT for the indicated times. Apoptotic cell death was quantified by TUNEL assay and enumerated by
flow cytometry. The left panel shows a representative experiment (B), and the percentage of TUNEL-positive cells in the graphs is shown as
the mean 6 SEM (n = 3).
(D) Effect of ROCK I inhibitor (Y-27632) on CPT-Mediated Apoptosis.
U2OS cells were treated with either DMSO or Y-27632 (3 mM) for 24 hr and exposed to 600 nM CPT for the indicated time periods (24 and 48 hr).
Cells were then assessed for apoptosis by TUNEL assay by both fluorescence microscopy and flow cytometry as described for (B and C).Overexpression of RhoE was able to inhibit ROCK I
activation (Figure 3B). These data suggest that p53 in-
duction of RhoE antagonizes ROCK I-mediated cellular
outcomes through a direct inhibition of ROCK I activity.
Given that RhoE expression inhibits ROCK I function
and exerts a pro-survival effect in response to p53 and
p53-dependent genotoxic stress, we investigated the
possibility that ROCK I-mediated apoptosis is one of
the apoptotic pathways activated in response to geno-
toxic stress and that RhoE modulates ROCK I-induced
apoptosis. However, the role of ROCK I in apoptosis
remains controversial [15, 17, 18, 20, 21], with studies
having been carried out in different cell types and with
a variety of death-inducing agents. Therefore, we firstneeded to confirm that genotoxic stress induced
ROCK I activation and cell death.
During apoptosis, the full-length ROCK I, at 160 kDa
(wt-ROCK I), is cleaved by caspase-3 into two frag-
ments, an active short form of ROCK I (s-ROCK I), at
130 kDa, and a 30 kDa cleaved fragment [14, 15, 22].
Cell lysates from CPT- or DMSO-treated U2OS cells
were immunoblotted with a C-terminal-specific anti-
body that detects the full-length wt-ROCK I and the 30
kDa fragment (154C, Becton Dickinson) or an N-termi-
nal-specific antibody (H-85, Santa Cruz) that recognizes
wt-ROCK I and active s-ROCK I. ROCK I cleavage was
detected in the CPT-treated cells but not in the DMSO-
treated cells (Figure 4A). Transient transfection of
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crease of both forms of ROCK I in CPT-treated cells,
whereas control shRNA had no effect on ROCK I levels
(Figure 4A). To exclude potential off-target effects, we
compared our designed ROCK I shRNA with that of the
commercially available siRNA (Santa Cruz), and both of
these reduced ROCK I expression (data not shown). In
all subsequent experiments, our designed RK1 siRNA
sequence was used. Whereas ROCK I shRNA had no ef-
fect on the induction of RhoE after DNA damage, RhoE
shRNA treatment resulted in increased ROCK I activation
(Figure 4A). Cleavage of PARP, an indicator of caspase-3
activation, was also reduced in ROCK I knockdown cells
as compared to the control cells upon CPT treatment
(Figure 4A), suggesting that ROCK I could affect cas-
pase-3 activation through a feed-forward loop. A recent
study also indicated that constitutively active ROCK I
resulted in an increase in caspase 3 activity, and inhibit-
ing ROCK I by shRNA suppressed further activation of
caspase 3 upon ceramide treatment [23].
To directly determine whether inhibition of ROCK I
could influence genotoxic-stress-induced apoptosis,
we used the TUNEL assay to analyze the level of apopto-
sis in CPT-treated U2OS cells in the presence of ROCK I
or control shRNA. After the reduction of ROCK I expres-
sion, the percentage of cells undergoing apoptosis after
CPT treatment was significantly decreased in compari-
son to that of control cells, whereas shRNA against
RhoE resulted in an increase in cell death in response
to CPT (Figure 4B). These data were confirmed with PI
staining and a DNA fragmentation assay (Figure S4).
Similar results were obtained in HCT116 cells (Figure 4C)
and mouse embryonic fibroblasts (MEF) (Figure S4),
confirming that this result is not cell-type-dependent.
We also examined whether the ROCK I inhibitor
Y-27632 [24] could affect the DNA-damage-induced
apoptotic response. Y-27632 prevented CPT-induced
cell death to a level similar to that achieved by ROCK I
shRNA transfection, as measured by a TUNEL assay
(Figure 4D).
Because the 130 kDa s-ROCK I is known to be the
active form of ROCK I generated in response to DNA
damage [14, 15], we investigated whether overexpres-
sion of s-ROCK I itself could result in apoptosis. U2OS
cells were infected with adenoviruses (Ad) expressing
s-ROCK I or wt-ROCK I. Overexpression of s-ROCK I
caused a significant induction of cell death as measured
by the number of TUNEL-positive cells (Figure S5), but
expression of wt-ROCK I failed to have any apoptotic
effect. The ability of s-ROCK I to induce apoptosis
was markedly abrogated in cells coinfected with Ad-
s-ROCK I and Ad-RhoE (Figure S5). Consistent with
previous studies [23], these data demonstrate a direct
correlation between the apoptotic response and ROCK I
activation. Together, these data indicate that ROCK I
may be an important mediator in apoptosis and that
RhoE is a critical negative regulator of ROCK I activity,
including ROCK I-mediated membrane blebbing and
cell death.
Our results demonstrate that RhoE is a novel p53 tran-
scriptional target gene that confers pro-survival effects
in the p53-dependent response to genotoxic stress.
Studies on RhoE indicate that it has two distinct func-
tions, one in regulating the actin cytoskeleton andanother in cell proliferation through inhibition of cell-
cycle progression [13]. Recently, it was shown that RhoE
expression is significantly reduced in prostate cancer
cells compared to normal prostate cells [25], suggesting
that RhoE has anti-proliferative effects [10]. However,
RhoE expression is elevated in pancreatic tumors, colon
cancer cells, and melanomas [26–28], suggesting vari-
ous roles for RhoE in different types of cancer. Our
data point to RhoE’s acting as a novel pro-survival factor
whereupon induction of RhoE leads to the survival and
propagation of cells that have sustained DNA damage.
This is supported by the fact that cells with silenced
RhoE show an increased propensity to undergo apopto-
sis in response to DNA damage. p53 pro-survival effec-
tors such as RhoE, which are induced in damaged
wt-p53-containing cells, play an important role in tissue
damage and repair in response to DNA-damaging
agents. Therefore, identifying the components of the
novel p53/RhoE/ROCK I signaling pathway will pro-
vide an opportunity for therapeutic intervention by re-
vealing novel drug-design targets that will potentially
maximize the p53-dependent response and sensitize
tumor cells to therapeutic drugs.
Supplemental Data
Supplemental Experimental Procedures and figures can be found
with this article online at http://www.current-biology.com/cgi/
content/full/16/24/2466/DC1/.
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